RxDoctor Payments Data

Yonide Lareche, NP

Nurse Practitioner · Worcester, MANPI 1639535073

Payments from drug & device makers

$484in general payments, 2019–2025

Across 16 payments — averaging $30.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$240
  • Teva Pharmaceuticals USA, Inc.$63
  • Takeda Pharmaceuticals U.S.A., Inc.$30
  • Indivior Inc.$30
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$28
  • Axsome Therapeutics, Inc.$25
  • plus $69 from 4 others

What the payments were for

  • Food & beverage$48099%
  • Education$51%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$484 in reported general payments places this provider in the 85th percentile of 3,855 nurse practitioner providers in Massachusetts.

See all nurse practitioner providers in Massachusetts

Medicare billing

Part B allowed, 2024
$14,541
Medicare patients
16
Services billed
132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole30$45,149
VraylarCariprazine Hcl27$37,908
Aripiprazole95$4,786
Olanzapine66$4,571
Paliperidone ErPaliperidone23$3,973
Clonazepam388$3,523
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine136$3,237
Zolpidem Tartrate258$2,745
Lurasidone Hcl39$2,492
Bupropion XlBupropion Hcl155$2,286
Trazodone Hcl178$2,217
Venlafaxine Hcl ErVenlafaxine Hcl109$2,061
Hydroxyzine Hcl142$1,968
Quetiapine Fumarate176$1,934
Asenapine Maleate12$1,729

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$240$45,14930 claims
AbbVieVraylar$23$37,90827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,855 nurse practitioner providers in Massachusetts.

Other nurse practitioner in Worcester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →